Research ExplorerPublicationsThe art of blocking ADP-ribosyltransferases (ARTs): nanobodi...

The art of blocking ADP-ribosyltransferases (ARTs): nanobodies as experimental and therapeutic tools to block mammalian and toxin ARTs

Standard

The art of blocking ADP-ribosyltransferases (ARTs): nanobodies as experimental and therapeutic tools to block mammalian and toxin ARTs. / Menzel, Stephan; Rissiek, Björn; Haag, Friedrich; Goldbaum, Fernando A; Nolte, Friedrich.

In: FEBS J, Vol. 280, No. 15, 01.08.2013, p. 3543-50.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Menzel, S, Rissiek, B, Haag, F, Goldbaum, FA & Nolte, F 2013, 'The art of blocking ADP-ribosyltransferases (ARTs): nanobodies as experimental and therapeutic tools to block mammalian and toxin ARTs', FEBS J, vol. 280, no. 15, pp. 3543-50. https://doi.org/10.1111/febs.12313

APA

Menzel, S., Rissiek, B., Haag, F., Goldbaum, F. A., & Nolte, F. (2013). The art of blocking ADP-ribosyltransferases (ARTs): nanobodies as experimental and therapeutic tools to block mammalian and toxin ARTs. FEBS J, 280(15), 3543-50. https://doi.org/10.1111/febs.12313

Vancouver

Menzel S, Rissiek B, Haag F, Goldbaum FA, Nolte F. The art of blocking ADP-ribosyltransferases (ARTs): nanobodies as experimental and therapeutic tools to block mammalian and toxin ARTs. FEBS J. 2013 Aug 1;280(15):3543-50. https://doi.org/10.1111/febs.12313

Bibtex

@article{f21c9c9c514740e8a4589ebb3387e3ac,
title = "The art of blocking ADP-ribosyltransferases (ARTs): nanobodies as experimental and therapeutic tools to block mammalian and toxin ARTs",
abstract = "In 1901, the first Nobel Prize in Physiology or Medicine was awarded to Emil von Behring for his ground-breaking discovery of serum therapy: serum from horses vaccinated with toxin-containing culture medium of Corynebacterium diphtheriae contained life-saving 'antitoxins'. The molecular nature of the ADP-ribosylating toxin and the neutralizing antibodies were unraveled only 50 years later. Today, von Behring's antibody therapy is being refined with a new generation of recombinant antibodies and antibody fragments. Nanobodies, which are single-domain antibodies derived from the peculiar heavy-chain antibodies of llamas and other camelids, are emerging as a promising new class of highly specific enzyme inhibitors. In this review, we illustrate the potential of nanobodies as tools to block extracellular and intracellular ADP-ribosyltransferases (ARTs), using the toxin-related membrane-bound mammalian ecto-enzyme ARTC2 and the actin-ADP-ribosylating Salmonella virulence plasmid factor B toxin of Salmonella enterica as examples.",
keywords = "ADP Ribose Transferases, Amino Acid Sequence, Animals, Bacterial Infections, Bacterial Toxins, Camelids, New World, Drug Delivery Systems, Humans, Molecular Sequence Data, Single-Domain Antibodies, Virulence Factors",
author = "Stephan Menzel and Bj{\"o}rn Rissiek and Friedrich Haag and Goldbaum, {Fernando A} and Friedrich Nolte",
note = "{\textcopyright} 2013 FEBS.",
year = "2013",
month = aug,
day = "1",
doi = "10.1111/febs.12313",
language = "English",
volume = "280",
pages = "3543--50",
journal = "FEBS J",
issn = "1742-464X",
publisher = "Wiley-Blackwell",
number = "15",

}

RIS

TY - JOUR

T1 - The art of blocking ADP-ribosyltransferases (ARTs): nanobodies as experimental and therapeutic tools to block mammalian and toxin ARTs

AU - Menzel, Stephan

AU - Rissiek, Björn

AU - Haag, Friedrich

AU - Goldbaum, Fernando A

AU - Nolte, Friedrich

N1 - © 2013 FEBS.

PY - 2013/8/1

Y1 - 2013/8/1

N2 - In 1901, the first Nobel Prize in Physiology or Medicine was awarded to Emil von Behring for his ground-breaking discovery of serum therapy: serum from horses vaccinated with toxin-containing culture medium of Corynebacterium diphtheriae contained life-saving 'antitoxins'. The molecular nature of the ADP-ribosylating toxin and the neutralizing antibodies were unraveled only 50 years later. Today, von Behring's antibody therapy is being refined with a new generation of recombinant antibodies and antibody fragments. Nanobodies, which are single-domain antibodies derived from the peculiar heavy-chain antibodies of llamas and other camelids, are emerging as a promising new class of highly specific enzyme inhibitors. In this review, we illustrate the potential of nanobodies as tools to block extracellular and intracellular ADP-ribosyltransferases (ARTs), using the toxin-related membrane-bound mammalian ecto-enzyme ARTC2 and the actin-ADP-ribosylating Salmonella virulence plasmid factor B toxin of Salmonella enterica as examples.

AB - In 1901, the first Nobel Prize in Physiology or Medicine was awarded to Emil von Behring for his ground-breaking discovery of serum therapy: serum from horses vaccinated with toxin-containing culture medium of Corynebacterium diphtheriae contained life-saving 'antitoxins'. The molecular nature of the ADP-ribosylating toxin and the neutralizing antibodies were unraveled only 50 years later. Today, von Behring's antibody therapy is being refined with a new generation of recombinant antibodies and antibody fragments. Nanobodies, which are single-domain antibodies derived from the peculiar heavy-chain antibodies of llamas and other camelids, are emerging as a promising new class of highly specific enzyme inhibitors. In this review, we illustrate the potential of nanobodies as tools to block extracellular and intracellular ADP-ribosyltransferases (ARTs), using the toxin-related membrane-bound mammalian ecto-enzyme ARTC2 and the actin-ADP-ribosylating Salmonella virulence plasmid factor B toxin of Salmonella enterica as examples.

KW - ADP Ribose Transferases

KW - Amino Acid Sequence

KW - Animals

KW - Bacterial Infections

KW - Bacterial Toxins

KW - Camelids, New World

KW - Drug Delivery Systems

KW - Humans

KW - Molecular Sequence Data

KW - Single-Domain Antibodies

KW - Virulence Factors

U2 - 10.1111/febs.12313

DO - 10.1111/febs.12313

M3 - SCORING: Journal article

C2 - 23627412

VL - 280

SP - 3543

EP - 3550

JO - FEBS J

JF - FEBS J

SN - 1742-464X

IS - 15

ER -